Melissa G. Lechner

3.8k total citations
56 papers, 2.3k citations indexed

About

Melissa G. Lechner is a scholar working on Oncology, Endocrinology, Diabetes and Metabolism and Epidemiology. According to data from OpenAlex, Melissa G. Lechner has authored 56 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Oncology, 16 papers in Endocrinology, Diabetes and Metabolism and 12 papers in Epidemiology. Recurrent topics in Melissa G. Lechner's work include Cancer Immunotherapy and Biomarkers (17 papers), Thyroid Cancer Diagnosis and Treatment (13 papers) and Neuroendocrine Tumor Research Advances (9 papers). Melissa G. Lechner is often cited by papers focused on Cancer Immunotherapy and Biomarkers (17 papers), Thyroid Cancer Diagnosis and Treatment (13 papers) and Neuroendocrine Tumor Research Advances (9 papers). Melissa G. Lechner collaborates with scholars based in United States, Australia and China. Melissa G. Lechner's co-authors include Alan L. Epstein, Trevor E. Angell, Jonathan S. LoPresti, Julie K. Jang, Sarah M. Russell, Garry S. Brody, Connor H. Church, Peisheng Hu, John R. Ohlfest and Katherine A. Murphy and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Circulation.

In The Last Decade

Melissa G. Lechner

48 papers receiving 2.2k citations

Peers

Countries citing papers authored by Melissa G. Lechner

Since Specialization

Citations

This map shows the geographic impact of Melissa G. Lechner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Melissa G. Lechner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Melissa G. Lechner more than expected).

Fields of papers citing papers by Melissa G. Lechner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Melissa G. Lechner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Melissa G. Lechner. The network helps show where Melissa G. Lechner may publish in the future.

Co-authorship network of co-authors of Melissa G. Lechner

This figure shows the co-authorship network connecting the top 25 collaborators of Melissa G. Lechner. A scholar is included among the top collaborators of Melissa G. Lechner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Melissa G. Lechner. Melissa G. Lechner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	1176 Anti-RANKL bone resorptive therapy increases immune related adverse events (irAEs) during checkpoint inhibitor therapy 2024 ·Regular and Young Investigator Award Abstracts ·(unknown), (unknown), (unknown), (unknown), (unknown), Maureen A. Su, (unknown), Melissa G. Lechner	0
2	Risk of severe immune-related adverse events in cancer patients with pre-existing autoimmunity receiving immune checkpoint inhibitor therapy 2024 ·PubMed ·(unknown), (unknown), (unknown), Melissa G. Lechner, Alexandra Drakaki	1
3	A New Twist on a Classic: Enhancing Radioiodine Uptake in Advanced Thyroid Cancer 2024 ·Clinical Cancer Research ·Melissa G. Lechner, Gregory A. Brent	0
4	Clonally expanded, thyrotoxic effector CD8 ⁺ T cells driven by IL-21 contribute to checkpoint inhibitor thyroiditis 2023 ·Science Translational Medicine ·Melissa G. Lechner, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Willy Hugo, (unknown), Alexandra Drakaki, Antoni Ribas, Trevor E. Angell, Maureen A. Su	19
5	Antigen presentation by clonally diverse CXCR5+ B cells to CD4 and CD8 T cells is associated with durable response to immune checkpoint inhibitors 2023 ·Frontiers in Immunology ·(unknown), Lu Sun, (unknown), Yanjun Zhang, (unknown), Robert M. Prins, Maureen A. Su, Melissa G. Lechner, Willy Hugo	18
6	Spectrum of Clinical Presentations, Imaging Findings, and HLA Types in Immune Checkpoint Inhibitor–Induced Hypophysitis 2023 ·Journal of the Endocrine Society ·Zoe Quandt, Stephanie Kim, Javier Villanueva‐Meyer, (unknown), Arabella Young, (unknown), Jinoos Yazdany, Gabriela Schmajuk, Stephanie Rush, Elad Ziv, Ana Luisa Perdigoto, Kevan C. Herold, Melissa G. Lechner, Maureen A. Su, James Tyrrell, Jeffrey A. Bluestone, Mark S. Anderson, Umesh Masharani	19
7	Safety and efficacy of immune checkpoint inhibitor cancer therapy in patients with preexisting type 1 diabetes mellitus 2023 ·Frontiers in Endocrinology ·(unknown), (unknown), Zoe Quandt, (unknown), Alexandra Drakaki, (unknown), Gino K. In, Trevor E. Angell, Melissa G. Lechner	4
8	Pathogenic TNF-α drives peripheral nerve inflammation in an Aire-deficient model of autoimmunity 2022 ·Proceedings of the National Academy of Sciences ·Yan Wang, (unknown), (unknown), (unknown), Mandy I. Cheng, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Willy Hugo, James F. Howard, Katherine M. Sheu, Alexander Hoffmann, Melissa G. Lechner, Maureen A. Su	22
9	Delayed Release of Amiodarone Causing Late-Onset Thyrotoxicosis 2022 ·(unknown), (unknown), Melissa G. Lechner	1
10	Optimal Thyroid Hormone Replacement Dose in Immune Checkpoint Inhibitor-Associated Hypothyroidism Is Distinct from Hashimoto's Thyroiditis 2022 ·Thyroid ·(unknown), (unknown), (unknown), Holly Wilhalme, (unknown), (unknown), Alexandra Drakaki, Trevor E. Angell, Melissa G. Lechner	18
11	Frequency of Thyroid Hormone Replacement After Lobectomy for Differentiated Thyroid Cancer 2021 ·Endocrine Practice ·(unknown), Melissa G. Lechner, (unknown), (unknown), Jiyoon Kim, Chi‐Hong Tseng, Angela M. Leung, Michael W. Yeh	25
12	COVID-19 Outcomes of Patients With Differentiated Thyroid Cancer: A Multicenter Los Angeles Cohort Study 2021 ·Endocrine Practice ·(unknown), (unknown), (unknown), (unknown), Trevor E. Angell, Gino K. In, Maureen A. Su, Melissa G. Lechner	9
13	MHC Class I Loss Is a Frequent Mechanism of Immune Escape in Papillary Thyroid Cancer That Is Reversed by Interferon and Selumetinib Treatment In Vitro 2014 ·Clinical Cancer Research ·Trevor E. Angell, Melissa G. Lechner, Julie K. Jang, Jonathan S. LoPresti, Alan L. Epstein	120
14	BRAF ^V600E in Papillary Thyroid Carcinoma Is Associated with Increased Programmed Death Ligand 1 Expression and Suppressive Immune Cell Infiltration 2014 ·Thyroid ·Trevor E. Angell, Melissa G. Lechner, Julie K. Jang, Adrian J. Correa, Jonathan S. LoPresti, Alan L. Epstein	108
15	Adenosine A1 receptor antagonist, L-97-1, improves survival and protects the kidney in a rat model of cecal ligation and puncture induced sepsis 2014 ·European Journal of Pharmacology ·Constance N. Wilson, (unknown), Melissa G. Lechner, George M. Matuschak, Andrew J. Lechner	13
16	Establishment and Characterization of a new Human Extragonadal Germ Cell Line, SEM-1, and its Comparison With TCam-2 and JKT-1 2013 ·Urology ·Sarah M. Russell, Melissa G. Lechner, (unknown), (unknown), Julie K. Jang, Clive R. Taylor, Leendert H. J. Looijenga, Christopher A. French, Alan L. Epstein	16
17	Immunogenicity of Murine Solid Tumor Models as a Defining Feature of In Vivo Behavior and Response to Immunotherapy 2013 ·Journal of Immunotherapy ·Melissa G. Lechner, (unknown), Keegan Barry-Holson, Trevor E. Angell, Katherine A. Murphy, Connor H. Church, John R. Ohlfest, Peisheng Hu, Alan L. Epstein	268
18	An In Vivo Immunotherapy Screen of Costimulatory Molecules Identifies Fc-OX40L as a Potent Reagent for the Treatment of Established Murine Gliomas 2012 ·Clinical Cancer Research ·Katherine A. Murphy, Melissa G. Lechner, Flavia E. Popescu, (unknown), Stacy A. Decker, Peisheng Hu, Jami R. Erickson, (unknown), (unknown), Andres Μ. Salazar, Michael R. Olin, Alan L. Epstein, John R. Ohlfest	29
19	Generation of tumor-targeted antibody–CpG conjugates 2012 ·Journal of Immunological Methods ·Zhongjun Li, Julie K. Jang, Melissa G. Lechner, Peisheng Hu, Leslie A. Khawli, Christopher A. Scannell, Alan L. Epstein	12
20	Gene expression in primate liver during viral hemorrhagic fever 2009 ·Virology Journal ·Mahmoud Djavani, Oswald Crasta, Yan Zhang, Juan Carlos Zapata, Bruno Sobral, Melissa G. Lechner, Joseph Bryant, Harry Davis, María S. Salvato	26

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact